We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Harvesting Method Produces Superior Transplantation Stem Cells

By LabMedica International staff writers
Posted on 19 Dec 2017
Hematopoietic stem cell transplantation is a potential curative therapy for malignant and nonmalignant diseases. More...
Improving the efficiency of stem cell collection and the quality of the cells acquired can broaden the donor pool and improve patient outcomes.

Currently, the most common way of harvesting hematopoietic (blood system) stem cells requires donors to receive daily injections of a drug called granulocyte colony-stimulating factor (G-CSF), which induces stem cells to pass from the bone marrow into the circulation. A new method of harvesting stem cells for bone marrow transplantation may make the donation process more convenient and less unpleasant for donors while providing cells that are superior to those acquired by current protocols.

A team of scientists collaborating with those at Massachusetts General Hospital (Boston, MA, USA) developed a rapid stem cell mobilization regimen utilizing a unique C-X-C chemokine receptor type 2 (CXCR2) agonist, growth regulated oncogene-beta (GROβ), and the CXCR4 antagonist Plerixafor (AMD3100). A single injection of both agents resulted in stem cell mobilization peaking within 15 minutes that was equivalent in magnitude to a standard multi-day regimen of granulocyte colony-stimulating factor (G-CSF).

In addition to determining the mechanisms by which combined administration of GROβ and AMD3100 produced enough stem cells so quickly, the team found that transplantation with these cells led to faster reconstitution of bone marrow and recovery of immune cell populations in mouse models. The stem cells produced by this procedure also show patterns of gene expression similar to those of fetal hematopoietic stem cells (HSCs), which are located in the liver, rather than the bone marrow. The team also determined that rapid mobilization results from synergistic signaling on neutrophils, resulting in enhanced matrix metallopeptidase 9 (MMP-9) release, and unexpectedly revealed genetic polymorphisms in MMP-9 that alter activity.

Jonathan Hoggatt, PhD, a professor and lead author of the study said, “This is an exciting time in bone marrow transplantation, as the number of diseases that can be treated or possibly even cured is increasing. With new gene therapy strategies being developed for diseases like sickle cell anemia, beta thalassemia and severe combined immunodeficiency, having enough high-quality, gene-altered cells can be a key bottleneck. Our ability to acquire highly engraftable HSCs with the GROβ and AMD3100 combination should significantly improve and expand the availability of those treatments.” The study was published on December 7, 2017, in the journal Cell.

Related Links:
Massachusetts General Hospital


Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
New
Automated Microscope
dIFine
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.